Safety of Monofluoroquinolones in Pediatric Patients | CMAC

Safety of Monofluoroquinolones in Pediatric Patients

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4):359-367

Section
Type
Journal article

Abstract

Two groups of children on therapy with monofluoroquinolones were enrolled in this open trial: 169 patients with cystic fibrosis (exacerbation period) and 55 patients with aplastic anemia (neutropenic phase); age was from 6 months to 16 years. The aim of the study was to compare tolerability (with the focus on arthrotoxicity) of ciprofloxacin, ofloxacin and pefloxacin during intermittent (15–50 mg/kg/day in cystic fibrosis patients) and prolonged continuous therapy (10–15 mg/kg/day in patients with aplastic anemia). Quinolone-induced arthropathy was reported in 8.4% of all cases, mainly during pefloxacin therapy (31.8%), and more frequently in patients with aplastic anemia (10.9% vs. 7.7%), only in pubertal children, and was fully reversible with no influence on the linear growth. Following the monofluoroquinolones use, residual jointrelated symptoms were not observed because monofuoroqinolones did not achieve chondrotoxic concentrations in cartilaginous structures.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared